Search research articles
Contact Us
Filters
Showing results (221-230 of 247) with videos related to
Page
of 25
Sort By:
Frontiers in Pharmacology
|
August 13, 2019
Tanshinone IIA Exerts Anti-Inflammatory and Immune-Regulating Effects on Vulnerable Atherosclerotic Plaque Partially <i>via</i> the TLR4/MyD88/NF-κB Signal Pathway
Zhuo Chen, Xiang Gao, Yang Jiao, et al.
The Oncologist
|
October 17, 2024
Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma
Bixia Tang, Jun Xiao, Zhihong Chi, et al.
Frontiers in Oncology
|
June 7, 2021
Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-<i>Ad hoc</i> Analyses of Pooled Data From Two Clinical Trials
Xue Bai, Jie Dai, Caili Li, et al.
Frontiers in Oncology
|
September 10, 2021
Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial
Lili Mao, Ya Ding, Xue Bai, et al.
Signal Transduction and Targeted Therapy
|
November 21, 2024
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial
Jiayong Liu, Xuan Wang, Zhongwu Li, et al.
Journal of Extracellular Vesicles
|
March 26, 2025
Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 Therapy
Linzi Sun, Xiaoting Wei, Qian Zhao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 26, 2021
Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway
Lili Mao, Jie Dai, Yabin Cao, et al.
Frontiers in Oncology
|
July 18, 2022
Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma
Lirui Tang, Xiaoting Wei, Caili Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2017
Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy
Yan Kong, Xinan Sheng, Xiaowen Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2019
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G<sub>4</sub> Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
Xinan Sheng, Xieqiao Yan, Zhihong Chi, et al.
Page
of 25
Search research articles
Search
Showing results (221-230 of 247) with videos related to
Sort By:
Page
of 25
Frontiers in Pharmacology
|
August 13, 2019
Tanshinone IIA Exerts Anti-Inflammatory and Immune-Regulating Effects on Vulnerable Atherosclerotic Plaque Partially <i>via</i> the TLR4/MyD88/NF-κB Signal Pathway
Zhuo Chen, Xiang Gao, Yang Jiao, et al.
The Oncologist
|
October 17, 2024
Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma
Bixia Tang, Jun Xiao, Zhihong Chi, et al.
Frontiers in Oncology
|
June 7, 2021
Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-<i>Ad hoc</i> Analyses of Pooled Data From Two Clinical Trials
Xue Bai, Jie Dai, Caili Li, et al.
Frontiers in Oncology
|
September 10, 2021
Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial
Lili Mao, Ya Ding, Xue Bai, et al.
Signal Transduction and Targeted Therapy
|
November 21, 2024
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial
Jiayong Liu, Xuan Wang, Zhongwu Li, et al.
Journal of Extracellular Vesicles
|
March 26, 2025
Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 Therapy
Linzi Sun, Xiaoting Wei, Qian Zhao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 26, 2021
Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway
Lili Mao, Jie Dai, Yabin Cao, et al.
Frontiers in Oncology
|
July 18, 2022
Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma
Lirui Tang, Xiaoting Wei, Caili Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2017
Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy
Yan Kong, Xinan Sheng, Xiaowen Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2019
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G<sub>4</sub> Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
Xinan Sheng, Xieqiao Yan, Zhihong Chi, et al.
Page
of 25